MX2013004710A - Anticuerpos para el tratamiento de vih. - Google Patents

Anticuerpos para el tratamiento de vih.

Info

Publication number
MX2013004710A
MX2013004710A MX2013004710A MX2013004710A MX2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A MX 2013004710 A MX2013004710 A MX 2013004710A
Authority
MX
Mexico
Prior art keywords
antibodies
cxcr4
treatment
hiv
relates
Prior art date
Application number
MX2013004710A
Other languages
English (en)
Spanish (es)
Inventor
Chistine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/913,300 external-priority patent/US9090686B2/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2013004710A publication Critical patent/MX2013004710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2013004710A 2010-10-27 2011-10-27 Anticuerpos para el tratamiento de vih. MX2013004710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
MX2013004710A true MX2013004710A (es) 2013-08-29

Family

ID=44913256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004710A MX2013004710A (es) 2010-10-27 2011-10-27 Anticuerpos para el tratamiento de vih.

Country Status (10)

Country Link
EP (1) EP2632953A1 (enExample)
JP (1) JP2014504147A (enExample)
KR (1) KR20140009174A (enExample)
CN (1) CN103180342A (enExample)
AU (1) AU2011322508A1 (enExample)
CA (1) CA2814908A1 (enExample)
MX (1) MX2013004710A (enExample)
RU (1) RU2013122770A (enExample)
WO (1) WO2012055980A1 (enExample)
ZA (1) ZA201302639B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961427B1 (en) * 2013-02-28 2020-03-25 Gnvie, Llc Hiv antigens and antibodies
AU2014359085B2 (en) * 2013-12-08 2017-11-02 Peptcell Limited HIV antigens and antibodies and compositions, methods and uses thereof
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
AU2011322508A1 (en) 2013-05-02
CN103180342A (zh) 2013-06-26
KR20140009174A (ko) 2014-01-22
EP2632953A1 (en) 2013-09-04
ZA201302639B (en) 2013-11-27
JP2014504147A (ja) 2014-02-20
CA2814908A1 (en) 2012-05-03
WO2012055980A1 (en) 2012-05-03
RU2013122770A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
MY155400A (en) Anti cxcr4 antibodies for the treatment of hiv
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NZ754051A (en) Novel antibodies and uses thereof
ZA202001564B (en) Anti- folate receptor alpha antibody conjugates and their uses
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX365382B (es) Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
MX2010003574A (es) Anticuerpos il-23.
SG194176A1 (en) Bcma (cd269/tnfrsf17) -binding proteins
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2012006430A (es) Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
MX2021005085A (es) Formulacion de anticuerpo.
WO2012047267A3 (en) Polyvalent immunogen
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24
MX2013004710A (es) Anticuerpos para el tratamiento de vih.
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
EP4061416A4 (en) POWASSAN VIRUS ANTIGENS AND RELATED COMPOSITIONS AND USES THEREOF FOR VACCINATION AND TREATING PATIENTS